{"id":1063277,"date":"2010-06-10T08:19:49","date_gmt":"2010-06-10T08:19:49","guid":{"rendered":"http:\/\/www.longevitymedicine.tv\/international-stem-cell-corporation-announces-company-update-conference-call-isco-chairman-kenneth-aldrich-to-discuss-status-of-the-company\/"},"modified":"2024-08-17T20:28:21","modified_gmt":"2024-08-18T00:28:21","slug":"international-stem-cell-corporation-announces-company-update-conference-call-isco-chairman-kenneth-aldrich-to-discuss-status-of-the-company-2","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/stem-cell-therapy\/international-stem-cell-corporation-announces-company-update-conference-call-isco-chairman-kenneth-aldrich-to-discuss-status-of-the-company-2.php","title":{"rendered":"International Stem Cell Corporation Announces Company Update Conference Call. ISCO Chairman Kenneth Aldrich to Discuss 'Status of the Company'"},"content":{"rendered":"

International Stem Cell Corporation (OTCBB:ISCO<\/a>), a California-based biotechnology company creating human stem cell lines through its patented parthenogenetic process that requires no use of fertilized embryos, today announced that it is has scheduled a conference call for June 15, 2010 at 10:00 a.m. PST. ISCO Chairman, Mr. Kenneth Aldrich will discuss the Company's newly issued patent, its recently completed financing, and the present status of the company and its vision for the coming year. The dial-in number for participants is 1 (800) 774-6070 and the pass code ID is 8273 225#. An alternate dial-in number is: 1 (630) 691-2753 and the pass code will be the same for both numbers. A replay of the call will be available on the home page of the company's web site at: http:\/\/www.internationalstemcell.com<\/a>. <\/p>

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)<\/b><\/i><\/p>

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells (hpSCs) from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCellTM<\/sup>, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology. More information is available at ISCO's website, http:\/\/www.internationalstemcell.com<\/a>. <\/p>

To subscribe to receive ongoing corporate communications please click on the following link: http:\/\/www.b2i.us\/irpass.asp?BzID=1468&to=ea&s=0<\/a>. <\/p>

FORWARD-LOOKING STATEMENTS:<\/b><\/i><\/p>

Statements pertaining to anticipated technological developments and therapeutic applications, and other opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as \"will,\" \"believes,\" \"plans,\" \"anticipates,\" \"expects,\" \"estimates,\") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and\/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.<\/i><\/p>

\"\"<\/span><\/p>

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com<\/a>
or
Brian Lundstrom, President
760-640-6383
bl@intlstemcell.com<\/a><\/p>

\"\"<\/div>","protected":false},"excerpt":{"rendered":"

International Stem Cell Corporation (OTCBB:ISCO), a California-based biotechnology company creating human stem cell lines through its patented parthenogenetic process that requires no use of fertilized embryos, today announced that it is has scheduled a conference call for June 15, 2010 … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[25,1246878],"tags":[],"class_list":["post-1063277","post","type-post","status-publish","format-standard","hentry","category-stem-cell-therapy","category-stem-cells"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1063277"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1063277"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1063277\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1063277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1063277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1063277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}